Trade VistaGen Therapeutics - VTGN CFD

Add to favourite

4.68

0.86%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.09

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

VistaGen Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	4.65
Open*	4.64
1-Year Change*	354.9%
Day's Range*	4.64 - 4.7
52 wk Range	1.62-24.71
Average Volume (10 days)	384.44K
Average Volume (3 months)	11.53M
Market Cap	129.71M
P/E Ratio	-100.00K
Shares Outstanding	27.02M
Revenue	810.50K
EPS	-4.76
Dividend (Yield %)	N/A
Beta	0.75
Next Earnings Date	Feb 5, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	4.65	-0.04	-0.85%	4.69	4.77	4.52
Apr 17, 2024	4.64	0.02	0.43%	4.62	4.74	4.62
Apr 16, 2024	4.62	0.13	2.90%	4.49	4.78	4.38
Apr 15, 2024	4.71	-0.17	-3.48%	4.88	4.92	4.59
Apr 12, 2024	4.87	-0.30	-5.80%	5.17	5.27	4.74
Apr 11, 2024	5.26	0.18	3.54%	5.08	5.37	5.04
Apr 10, 2024	5.07	-0.01	-0.20%	5.08	5.16	5.00
Apr 9, 2024	5.32	0.18	3.50%	5.14	5.34	5.14
Apr 8, 2024	5.12	0.10	1.99%	5.02	5.19	4.94
Apr 5, 2024	5.01	-0.16	-3.09%	5.17	5.18	4.94
Apr 4, 2024	5.23	-0.12	-2.24%	5.35	5.68	5.23
Apr 3, 2024	5.35	0.12	2.29%	5.23	5.48	5.22
Apr 2, 2024	5.34	0.21	4.09%	5.13	5.42	5.02
Apr 1, 2024	5.36	0.00	0.00%	5.36	5.69	5.03
Mar 28, 2024	5.22	0.68	14.98%	4.54	5.58	4.47
Mar 27, 2024	4.53	0.16	3.66%	4.37	4.61	4.28
Mar 26, 2024	4.32	0.07	1.65%	4.25	4.39	4.17
Mar 25, 2024	4.23	0.06	1.44%	4.17	4.38	4.13
Mar 22, 2024	4.12	-0.09	-2.14%	4.21	4.21	4.08
Mar 21, 2024	4.18	0.01	0.24%	4.17	4.26	4.10

VistaGen Therapeutics Events

Time (UTC)	Country	Event
Wednesday, May 29, 2024
Time (UTC) 17:00	Country US	Event Vistagen Therapeutics Inc Extraordinary Shareholders Meeting Vistagen Therapeutics Inc Extraordinary Shareholders Meeting Forecast - Previous -
Wednesday, June 26, 2024
Time (UTC) 20:00	Country US	Event Q4 2024 Vistagen Therapeutics Inc Earnings Release Q4 2024 Vistagen Therapeutics Inc Earnings Release Forecast - Previous -
Tuesday, September 24, 2024
Time (UTC) 21:00	Country US	Event Vistagen Therapeutics Inc Annual Shareholders Meeting Vistagen Therapeutics Inc Annual Shareholders Meeting Forecast - Previous -

View all events

Annual
Quarterly

	2023	2022	2021	2020	2019
Total revenue	-0.2273	1.1089	1.0895	0	0
Revenue	-0.2273	1.1089	1.0895	0	0
Total Operating Expense	59.0407	48.8878	19.0233	20.8015	24.579
Selling/General/Admin. Expenses, Total	14.6636	13.48	6.5469	7.4273	7.4578
Research & Development	44.2751	35.3108	12.4124	13.3252	17.0495
Depreciation / Amortization	0.102	0.097	0.064	0.049	0.049
Unusual Expense (Income)				0	0.0227
Other Operating Expenses, Total
Operating Income	-59.268	-47.7789	-17.9338	-20.8015	-24.579
Interest Income (Expense), Net Non-Operating	0.0262	0.0199	0.0016	0.0301	-0.008
Other, Net		0	0.0006
Net Income Before Taxes	-59.2418	-47.759	-17.9316	-20.7714	-24.587
Net Income After Taxes	-59.2477	-47.7624	-17.9342	-20.774	-24.5896
Net Income Before Extra. Items	-59.2477	-47.7624	-17.9342	-20.774	-24.5896
Net Income	-59.2477	-47.7624	-17.9342	-20.774	-24.5896
Total Adjustments to Net Income	0	-0.9451	-24.3856	-1.2636	-1.1399
Income Available to Common Excl. Extra. Items	-59.2477	-48.7075	-42.3198	-22.0376	-25.7295
Income Available to Common Incl. Extra. Items	-59.2477	-48.7075	-42.3198	-22.0376	-25.7295
Diluted Net Income	-59.2477	-48.7075	-42.3198	-22.0376	-25.7295
Diluted Weighted Average Shares	6.95875	6.59929	2.87112	1.46217	0.95199
Diluted EPS Excluding Extraordinary Items	-8.51413	-7.38072	-14.7398	-15.0718	-27.0271
Diluted Normalized EPS	-8.51413	-7.38072	-14.7398	-15.0718	-27.0116
Total Extraordinary Items

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0.1776	0.1756	0.1796	-0.8925	0.3101
Revenue	0.1776	0.1756	0.1796	-0.8925	0.3101
Total Operating Expense	7.1754	12.4147	9.9461	16.5968	20.0832
Selling/General/Admin. Expenses, Total	2.9782	3.0774	3.0921	3.7023	4.7918
Research & Development	4.1672	9.3083	6.826	12.8675	15.2734
Depreciation / Amortization	0.03	0.029	0.028	0.027	0.018
Operating Income	-6.9978	-12.2391	-9.7665	-17.4893	-19.7731
Interest Income (Expense), Net Non-Operating	0.0972	0.0125	0.0053	0.0061	0.0023
Other, Net
Net Income Before Taxes	-6.9006	-12.2266	-9.7612	-17.4832	-19.7708
Net Income After Taxes	-6.9031	-12.227	-9.7612	-17.4832	-19.7763
Net Income Before Extra. Items	-6.9031	-12.227	-9.7612	-17.4832	-19.7763
Net Income	-6.9031	-12.227	-9.7612	-17.4832	-19.7763
Total Adjustments to Net Income		0	0	0	0
Income Available to Common Excl. Extra. Items	-6.9031	-12.227	-9.7612	-17.4832	-19.7763
Income Available to Common Incl. Extra. Items	-6.9031	-12.227	-9.7612	-17.4832	-19.7763
Diluted Net Income	-6.9031	-12.227	-9.7612	-17.4832	-19.7763
Diluted Weighted Average Shares	7.37701	6.95875	6.89391	6.89302	6.88587
Diluted EPS Excluding Extraordinary Items	-0.93576	-1.75707	-1.41592	-2.53636	-2.87201
Diluted Normalized EPS	-0.93576	-1.75707	-1.41592	-2.53636	-2.87201
Dividends per Share - Common Stock Primary Issue	0		0	0	0

Annual
Quarterly

	2023	2022	2021	2020	2019
Total Current Assets	17.5074	70.998	104.118	1.5802	13.6512
Cash and Short Term Investments	16.6376	68.1353	103.108	1.3551	13.1003
Cash & Equivalents	16.6376	68.1353	103.108	1.3551	13.1003
Prepaid Expenses	0.528	2.4079	0.8351	0.2251	0.2509
Total Assets	21.0892	74.6434	108.281	5.7723	14.0117
Property/Plant/Equipment, Total - Net	2.7676	3.0763	3.587	3.7892	0.3127
Other Long Term Assets, Total	0.8142	0.5691	0.5768	0.4029	0.0478
Total Current Liabilities	4.5674	5.7651	4.189	2.7713	2.8009
Accounts Payable	2.4731	2.7586	0.8383	1.8366	1.055
Accrued Expenses	1.273	1.7625	1.9275	0.8749	1.6856
Notes Payable/Short Term Debt	0.1053	0	0	0	0
Current Port. of LT Debt/Capital Leases	0.0017	0	0.003	0.0598	0.0603
Total Liabilities	9.0092	9.9281	16.3028	11.5017	6.9365
Total Long Term Debt	0.0074	0	0	0.003	0.0063
Long Term Debt
Capital Lease Obligations	0.0074		0	0.003	0.0063
Other Liabilities, Total	4.4344	4.163	12.1138	8.7274	4.1293
Total Equity	12.08	64.7153	91.9785	-5.7294	7.0752
Preferred Stock - Non Redeemable, Net		0	0.0043	0.004	0.004
Common Stock	0.0073	0.2067	0.1808	0.0493	0.0428
Additional Paid-In Capital	342.892	336.081	315.603	200.093	192.13
Retained Earnings (Accumulated Deficit)	-326.852	-267.604	-219.842	-201.907	-181.133
Treasury Stock - Common	-3.9681	-3.9681	-3.9681	-3.9681	-3.9681
Total Liabilities & Shareholders’ Equity	21.0892	74.6434	108.281	5.7723	14.0117
Total Common Shares Outstanding	7.31088	6.8847	6.02052	1.64027	1.42062
Total Preferred Shares Outstanding		0	3.94968	3.97825	3.97825
Total Receivables, Net	0.2747	0.3379	0.0406	0	0.3
Property/Plant/Equipment, Total - Gross	3.961	4.3451	4.7411	4.8257	1.2461
Accumulated Depreciation, Total	-1.1934	-1.2688	-1.1541	-1.0365	-0.9334
Other Current Assets, Total	0.0671	0.1169	0.1335
Other Current Liabilities, Total	0.7143	1.244	1.4202

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	39.0762	11.5788	17.5074	26.0575	36.9138
Cash and Short Term Investments	37.6084	9.6223	16.6376	25.0373	35.2872
Cash & Equivalents	37.6084	9.6223	16.6376	25.0373	35.2872
Total Receivables, Net		0.48	0.2747	0.1541	0.1541
Prepaid Expenses	1.3933	1.4094	0.528	0.7991	1.4055
Other Current Assets, Total	0.0745	0.0671	0.0671	0.067	0.067
Total Assets	42.1958	15.0323	21.0892	29.7088	40.7017
Property/Plant/Equipment, Total - Net	2.4893	2.6296	2.7676	2.9048	3.0245
Property/Plant/Equipment, Total - Gross		3.8545	3.961	4.2551	4.3442
Accumulated Depreciation, Total		-1.2249	-1.1934	-1.3503	-1.3197
Other Long Term Assets, Total	0.6303	0.8239	0.8142	0.7465	0.7634
Total Current Liabilities	2.9095	4.0492	4.5674	4.2874	6.0454
Accounts Payable	1.305	1.6232	2.4731	1.5988	2.9578
Accrued Expenses	0.8097	0.9258	1.273	1.5556	1.6438
Notes Payable/Short Term Debt	0	0.7842	0.1053	0.4191	0.73
Current Port. of LT Debt/Capital Leases	0.0018	0.0017	0.0017	0.0016	0.0015
Other Current Liabilities, Total	0.793	0.7143	0.7143	0.7123	0.7123
Total Liabilities	6.5506	8.1833	9.0092	9.0343	11.0967
Total Long Term Debt	0.0065	0.007	0.0074	0.0079	0.0083
Capital Lease Obligations	0.0065	0.007	0.0074	0.0079	0.0083
Other Liabilities, Total	3.6346	4.1271	4.4344	4.739	5.043
Total Equity	35.6452	6.849	12.08	20.6745	29.605
Preferred Stock - Non Redeemable, Net
Common Stock	0.012	0.0079	0.0073	0.2071	0.207
Additional Paid-In Capital	379.944	344.564	342.892	339.06	338.23
Retained Earnings (Accumulated Deficit)	-340.342	-333.755	-326.852	-314.625	-304.863
Treasury Stock - Common	-3.9681	-3.9681	-3.9681	-3.9681	-3.9681
Total Liabilities & Shareholders’ Equity	42.1958	15.0323	21.0892	29.7088	40.7017
Total Common Shares Outstanding	12.0122	7.87515	7.31088	6.89652	6.89386
Total Preferred Shares Outstanding

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-47.7624	-17.9342	-20.774	-24.5896	-14.3459
Cash From Operating Activities	-45.2565	-12.0735	-15.757	-14.5275	-9.0583
Cash From Operating Activities	0.1535	0.1176	0.1031	0.0912	0.0807
Non-Cash Items	4.2703	2.6661	5.089	8.2527	4.3877
Cash Taxes Paid	0.0034	0.0026	0.0026	0.0026	0.0024
Cash Interest Paid	0.0003	0.0133	0.0148	0.008	0.0089
Changes in Working Capital	-1.9179	3.077	-0.1751	1.7182	0.8192
Cash From Investing Activities	-0.2004	-0.2754	0	-0.174	-0.0016
Capital Expenditures	-0.2004	-0.2754	0	-0.174	-0.0016
Cash From Financing Activities	10.4839	114.102	4.0118	17.4235	16.5169
Issuance (Retirement) of Stock, Net	6.4468	114.484	4.3084	17.6467	16.7223
Issuance (Retirement) of Debt, Net	-0.003	-0.382	-0.2966	-0.2232	-0.2054
Net Change in Cash	-34.973	101.753	-11.7452	2.722	7.457
Financing Cash Flow Items	4.0401

	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021
Net income/Starting Line	-47.0207	-37.2595	-19.7763	-47.7624	-31.074
Cash From Operating Activities	-42.2424	-32.3091	-15.9683	-45.2565	-29.668
Cash From Operating Activities	0.0962	0.0656	0.0323	0.1535	0.1149
Non-Cash Items	3.1102	2.1849	1.0539	4.2703	2.7735
Changes in Working Capital	1.5719	2.6999	2.7218	-1.9179	-1.4824
Cash From Investing Activities	-0.212	-0.1995	-0.1751	-0.2004	-0.2003
Capital Expenditures	-0.212	-0.1995	-0.1751	-0.2004	-0.2003
Cash From Financing Activities	-0.6436	-0.3395	-0.0055	10.4839	10.4602
Issuance (Retirement) of Stock, Net	0.1675	0.1605	0.1561	6.4468	6.4229
Issuance (Retirement) of Debt, Net	-0.7215	-0.4104	-0.1022	-0.003	-0.0028
Net Change in Cash	-43.098	-32.8481	-16.1489	-34.973	-19.4081
Financing Cash Flow Items	-0.0896	-0.0896	-0.0594	4.0401	4.0401
Cash Taxes Paid				0.0034
Cash Interest Paid				0.0003

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

VistaGen Therapeutics Company profile

About Vistagen Therapeutics Inc

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).

Financial summary

BRIEF: For the nine months ended 31 December 2021, Vistagen Therapeutics Inc revenues increased 65% to $1.1M. Net loss applicable to common stockholders increased from $12.8M to $32M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase from $5.2M to $21.9M (expense).

Equity composition

Common Stock $0.0005 Par, 6/11, 200M auth., 11,697,414 issd. Insiders own 28.61%. 06/10, Exchange changed from NYSE to OTC Pink Sheets. 06/11, 2-for-1 stock split. 08/14, 1-for-20 Reverse stock split.

Industry:

Bio Therapeutic Drugs

343 Allerton Avenue
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024